Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome

Rand, Jacob H.; Wu, Xiao‐Xuan; Lapinski, Robert; Heerde, Waander L. van; Reutelingsperger, Chris; Chen, Pojen P.; Ortel, Thomas L.

doi:10.1182/blood-2004-01-0203

Cited by 93 publications

(77 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We compared the results with the effect on thrombin time, a PL-independent clotting time (CT). Moreover, we compared the effect of CRP with that of annexin V (AnV), a potent endothelial surface anticoagulant based on its ability to displace PL-dependent coagulation factors by binding to negatively charged PL, including phosphatidylserine (PS) and PE [1,7] . We attempted to visualize the binding of CRP to the PL surface by flow cytometry.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Interference of C-reactive protein with clotting times

Devreese

Verfaillie

Bisschop

et al. 2015

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

mentioning

confidence: 99%

“…The final concentration range of AnV (Sigma-Aldrich, St. Louis, MO, USA) (0 -0.09 -0.18 -0.36 -0.72 -1.14 μ M) was based on current literature [7] .…”

mentioning

confidence: 99%

Interference of C-reactive protein with clotting times

Devreese

Verfaillie

Bisschop

et al. 2015

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

“…The AnxA5 anticoagulant function might depend on its 4 well-established property to self-assemble on PS-containing membranes into an extensive two-dimensional crystal lattice [42] that hinders the assembly of the procoagulant complexes. In line with such protective function in the blood clotting regulation, anti-AnxA5 autoantibodies are found in patients suffering from antiphospholipid syndrome [43], a disease that manifests clinically as recurrent thrombotic events and is associated with fetal loss [44]. The occurrence of AnxA5 autoantibodies [45] is also linked to autoimmune disorders [46] also observed in some patients suffering from multiple sclerosis or systemic lupus erythematosus.…”

Section: Coagulationmentioning

confidence: 85%

Annexins in Translational Research: HIDDEN Treasures to Be Found

Schloer¹,

Pajonczyk²,

Rescher³

2018

Preprint

View full text Add to dashboard Cite

The vertebrate annexin superfamily (AnxA) consists of 12 members of a calcium (Ca 2+ ) and phospholipid binding protein family which share a high structural homology. In keeping with this hallmark feature, annexins have been implicated in the Ca 2+ -controlled regulation of a broad range of membrane events. In this review, we identify and discuss several themes of annexin actions that hold a potential therapeutic value, namely the regulation of the immune response and the control of tissue homeostasis, and that repeatedly surface in the annexin activity profile. Our aim is to identify and discuss those annexin properties which might be exploited from a translational science and specifically clinical point of view.

show abstract

“…Similarly to the TGT tests the various variants require validation for their relevance as PD methods and addition to diagnosis [35,36] Lupus anticoagulant tests As is well known, lupus testing relies on the determination of prolongation of clotting tests, while 'by contrast' the feared complication is thrombotic.This indicates that the clotting tests utilized are pharmacokinetic rather than functional. More recently Rand et al [37] proposed other tests which seem to reflect the (patho-)physiology better as they study increased coagulation in relation to thrombosis. The value of this approach will become a topic of future research and a possible guide to treatment.…”

Section: The Prothrombin Time Test (Inr)mentioning

confidence: 99%

Introduction to haemostasis from a pharmacodynamic perspective

Kluft

Burggraaf

2011

Brit J Clinical Pharma

View full text Add to dashboard Cite

Biochemical characterization of the haemostatic system has advanced significantly in the past decades. Sub-systems, such as coagulation, fibrinolysis, blood cells and platelets and the vessel wall have been studied by specialists, mostly separately and independently. The time has come to integrate the approaches, and, in particular, to develop tests to document the state of the whole system and to have available adequate pharmacodynamic tests to evaluate treatments. Many examples are available to show that traditional general methods of clotting and lysis do not provide the information that is desired. The present tendency is to use specific methods for specific factors or effects which are very limited in pharmacological information. There is also increasing awareness of the occurrence of rather broad interindividual variability in the haemostatic system. This suggests that individually tailored treatments are required. This is the more relevant since haemostasis is a balance and treatment should be positioned between efficacy and safety. The conclusion is reached that there is a need for integrated or global methods or sets of methods that reflect the complexity and individual status appropriately and allow the practitioner to judge the effects of interventions and their individual aspects. IntroductionMaintenance of blood fluidity within the vascular system is an important physiological theme. At the same time, the local formation of a clot serves to assist in preventing excessive blood leakages, and in aiding tissue repair. In addition clot formation is involved in host defence.A balance with, on the one hand, a deviation in excessive clot formation and, on the other hand, defective clot formation was proposed originally by Astrup in 1958 [1]. The system requires delicate biochemical regulation to maintain this balance and to serve the various functions adequately.Deviations in the haemostasis of excessive clot formation or thrombosis are involved in arterial diseases such as myocardial infarction and ischaemic stroke, in venous diseases such as deep vein thrombosis and pulmonary embolism, and in organ failure during trauma and infections.This is a major cause of death and disabilities. Another deviation concerns defects in clot formation and subsequent bleeding, known from congenital deficiencies in clotting factors such as factor VIII and IX, but also potentially life threatening during trauma and a major issue in critical care medicine.Many treatment options to reinforce the system or to inhibit parts of it have been developed and are still under active development. These treatments inevitably interfere with the balance mentioned earlier and besides the intended effect, the opposite effect (bleeding or thrombosis) is always associated with the treatments as a safety issue.The present introduction evaluates recent developments in concepts in haemostasis, the status of biomarker analysis and the desired development of pharmacodynamic tests. Development of concepts Biochemical conceptsHaemostasis is regulate...

show abstract

Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome

Cited by 93 publications

References 33 publications

Interference of C-reactive protein with clotting times

Interference of C-reactive protein with clotting times

Annexins in Translational Research: HIDDEN Treasures to Be Found

Introduction to haemostasis from a pharmacodynamic perspective

Contact Info

Product

Resources

About